Cite
HARVARD Citation
Nastoupil, L. et al. (n.d.). CHEMO‐FREE TRIPLET COMBINATION OF TGR‐1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL.. Hematological oncology. pp. 112-113. [Online].